Zai Lab Limited (HKG:9688)
Hong Kong · Delayed Price · Currency is HKD 28.90
-0.45 (-1.53%)
Aug 1, 2025, 4:08 PM HKT
Zai Lab Employees
Zai Lab had 1,869 employees as of December 31, 2024. The number of employees decreased by 306 or -14.07% compared to the previous year.
Employees
1,869
Change (1Y)
-306
Growth (1Y)
-14.07%
Revenue / Employee
$1,741,389
Profits / Employee
-$1,049,306
Market Cap
31.96B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,869 | -306 | -14.07% |
| Dec 31, 2023 | 2,175 | 139 | 6.83% |
| Dec 31, 2022 | 2,036 | 85 | 4.36% |
| Dec 31, 2021 | 1,951 | 757 | 63.40% |
| Dec 31, 2020 | 1,194 | 502 | 72.54% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BeOne Medicines | 11,000 |
| Hansoh Pharmaceutical Group Company | 8,989 |
| Innovent Biologics | 5,659 |
| JD Health International | 3,564 |
| Akeso | 3,035 |
| WuXi Biologics | 12,575 |
| Sino Biopharmaceutical | 24,379 |
| CSPC Pharmaceutical Group | 21,400 |
Zai Lab News
- 23 days ago - Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025 - Business Wire
- 4 weeks ago - Amgen, Zai Lab succeed in gastric cancer study - Seeking Alpha
- 4 weeks ago - Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer - Business Wire
- 7 weeks ago - Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025 - Business Wire
- 2 months ago - NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial - Benzinga
- 2 months ago - Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting - Business Wire
- 2 months ago - Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting - Business Wire
- 2 months ago - Zai Lab Announces Participation in Investor Conferences in June 2025 - Business Wire